Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments

Purpose It is known that 30% of clear cell renal cell carcinomas (ccRCC) will develop progressive disease after surgical treatment. These patients with high-risk ccRCC require adjuvant therapy after nephrectomy or resection of metastases. The article presents an overview of the results of recent stu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	World journal of urology 2023-07, Vol.41 (7), p.1855-1859
Hauptverfasser:	Tsimafeyeu, Ilya, Basin, Michael F., Bratslavsky, Gennady
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Clear cell-type renal cell carcinoma Clinical trials Combined Modality Therapy Humans Immune checkpoint inhibitors Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Medicine Medicine & Public Health Metastases Metastasis Neoplasm Recurrence, Local Nephrectomy Nephrology Nivolumab - therapeutic use Oncology Original Article Pembrolizumab Randomized Controlled Trials as Topic Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!